Eli Lilly to buy AtaiBeckley for up to $3.8 billion
2026-07-19 14:50:54
According to CNBC, Eli Lilly will acquire clinical-stage psychedelic drug developer AtaiBeckley for up to $3.8 billion, underscoring Big Pharma's growing interest in therapies for mental health conditions. AtaiBeckley's lead drug, BPL-003, is a synthetic form of 5-MeO-DMT given as an intranasal spray for treatment-resistant depression, and the company said last year that a Phase 2b study showed rapid and durable symptom reductions. BPL-003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and is now in Phase 3 trials. Jefferies analysts said Phase 3 success by early 2029 could open a $1 billion to $2 billion opportunity in treatment-resistant depression.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
